期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 176, 期 7, 页码 817-831出版社
WILEY
DOI: 10.1111/bph.14572
关键词
-
资金
- National Natural Science Foundation of China [31671195, 31471208, 31871381]
- Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College, HUST
- Front Youth Academic Team Program of HUST
- Natural Science Foundation of Hubei Province [2014CFA021]
The transcription factor p53 is known as the guardian of the genome for its powerful anti-tumour capacity. However, mutations of p53 that undermine their protein structure, resulting in loss of tumour suppressor function and gain of oncogenic function, have been implicated in more than half of human cancers. The crucial role of mutant forms of p53 in cancer makes it an attractive therapeutic target. A large number of candidates, including low MW compounds, peptides, and nucleic acids, have been identified or designed to rescue p53 mutants and reactivate their anti-tumour capacity through a variety of mechanisms. In this review, we summarize the progress made in the reactivation of mutant forms of p53, focusing on the pharmacological mechanisms of the reactivators of p53 mutants.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据